ARZERRA® (ofatumumab) Press Kit
April 17, 2014 GSK and Genmab receive FDA approval for Arzerra® (ofatumumab) as first-line treatment in combination with chlorambucil for patients with Chronic Lymphocytic Leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate
Full US Prescribing Information
CLL Backgrounder (PDF)
Photos & Videos
Note to user, 'Right click', 'Save Target As' to download image.